You are here: Industry Insights > hepatocellular carcinoma

News List

Pride of New Chinese Medicine, Icaritin To Be Included in the Priority Review as the First-line Treatment for Hepatocellular PharmaSources/Dopine
May 25, 2021
CDE official website recently disclosed that the marketing application of the Category 1.2 innovative traditional Chinese medicine "Icaritin" of Shenogen Pharma Group/Kangerfu Pharmaceutical would be included in the priority review as scheduled
Tetra Bio-Pharma Requests Meeting with FDA on Hepatocellular Carcinoma Drug americanpharmaceuticalreview
December 16, 2019
Tetra Bio-Pharma will be requesting a meeting with the U.S. Food and Drug Administration (FDA) to discuss the drug development program for its Orphan Drug candidate HCC011 ...
Tetra Bio-Pharma Receives ODD for Hepatocellular Carcinoma Treatment americanpharmaceuticalreview
December 09, 2019
Tetra Bio-Pharma has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.
FDA Approves Cabozantinib for Hepatocellular Carcinoma americanpharmaceuticalreview
January 17, 2019
On January 14, 2019, the Food and Drug Administration (FDA) approved cabozantinib (CABOMETYX, Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib....
Nature Review: Current Situation of the Global Liver Cancer Drug Market Weiyi
December 11, 2018
Liver cancer has become one of the tumors with high fatality rate among cancers in the U.S., and is mainly treated through systemic palliative care in the advanced stage.
BeiGene Initiates Global Phase III Trial of Anti-PD-1 Antibody Tislelizumab in Patients With Hepatoc biospace
January 03, 2018
BeiGene today announced that the first patient in the world in December 2017 was tislelizumab, an investigational anti-PD-1 antibody, for the phase 3 clinical trial of patients with previously untreated advanced hepatocellular carcinoma
EU approved Bayer's Stivarga for the Second-Line Systemic Treatment of Liver Cancer firstwordpharma
August 08, 2017
The approval for the first treatment advance in nearly 10 years is based on data from the Phase III RESORCE research.
FDA accepts for priority review BMS’s application for Opdivo in previously treated hepatocellular ca cphi-online
May 31, 2017
Application is based on results from the Phase I/II CheckMate -040 trial.
FDA Expands Approved Use of Stivarga (regorafenib) to Treat Hepatocellular Carcinoma drugs.com
April 28, 2017
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.